Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies

Sponsored by UCB

Feb 19, 2025 11:00 am

(171.71 KB)

(62.83 KB)

Presentation

Alice Gottlieb, M.D.

Author(s):

Diamant Thaçi, Akihiko Asahina, Wolf‑Henning Boehncke, Alice B. Gottlieb, Mark Lebwohl, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Joseph F. Merola

Abstract or description:

This study aimed to assess the efficacy and safety of bimekizumab (BKZ) to 2 years in patients with psoriatic arthritis (PsA) who also had skin and nail psoriasis, and were biologic disease-modifying antirheumatic drug (bDMARD)-naïve or had prior inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).

These studies were funded by UCB. All costs associated with development of this presentation were funded by UCB.

Long-term maintenance of response of an IL-23i in PsA

Time to first musculoskeletal response of an IL-23i in PsA

Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica

Effectiveness of IL-6 Receptor Inhibitors versus Methotrexate or any Conventional Immunomodulators in Patients with Steroid Refractory Polymyalgia Rheumatica